Therapeutic Discovery Articles & Analysis
83 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. ...
This integral development aims to enhance the understanding of depressive disorders and expedite the discovery of innovative therapeutic solutions. Depression is a pervasive global health challenge that affects millions of individuals, with current treatment options often proving ineffective or inaccessible. With the advancement of biotechnology and biological ...
This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. ...
Stem cells have revolutionized cell-based therapeutics, drug discovery and many other scientific fields. However, despite significant advancements in iPSC culture, several challenges remain regarding the reliability, reproducibility and consistency of cell cultures, assays and data. ...
Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. ...
This opens new avenues for groundbreaking discoveries and therapeutic breakthroughs. High-Throughput and Swift Turnaround: CD Genomics' cutting-edge NGS platform enables the simultaneous analysis of multiple samples, significantly reducing turnaround times without compromising data quality. ...
This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. Protein-protein interactions serve as the building blocks of various cellular processes, orchestrating critical functions within living organisms. Gaining a deeper ...
Through their Whole Exome Sequencing service, researchers and clinicians gain the means to unravel the mysteries of the exome, facilitating groundbreaking discoveries and personalized therapeutic interventions. The senior expert at CD Genomics, expressed their enthusiasm for the WES service, stating, "Our Whole Exome Sequencing service represents a significant ...
Our unique combination of tissue engineering technology with assay automation and sample miniaturization offers a rapid and cost effective platform for unprecedented therapeutic discovery. IVS is addressing a significant, well-recognized but underserved problem with a technology that can effectively fill the gap in the existing large market. ...
Our unique combination of tissue engineering technology with assay automation and sample miniaturization offers a rapid and cost effective platform for unprecedented therapeutic discovery. IVS is addressing a significant, well-recognized but underserved problem with a technology that can effectively fill the gap in the existing large market. ...
Her leadership and extensive drug development experience at Amgen, Merck, and Greenfire Bio aligns with the company’s drug discovery interests across multiple therapeutic areas, including cardio-metabolic, pulmonary, inflammatory ophthalmology, renal and fibrotic diseases. ...
A third key strategic element to enhance sales growth are the acquired platform companies BlueRock Therapeutics (BlueRock), Asklepios Biopharmaceutical (AskBio) and Vividion Therapeutics (Vividion), with their industry-leading scientific innovation which have already successfully diversified and strengthened Bayer’s pipeline. ...
ByBayer AG
With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world class iPSC-based solutions to therapeutic developers. We are continuing to build our leadership teams by recruiting Gustavo Mahler as Chief Executive Officer. ...
Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director. ...
According to the official speaker from Creative BioMart, based on MHC-like complexes that can directly identify and isolate antigen-specific T cells or screen and identify MHC-like antigens that can be used for vaccine development, the company can provide two therapeutic development services: cell therapy and vaccine development. Service Range MHC Neoepitopes ...
“We’re also excited to explore partnerships with biopharma companies looking to benefit from the mapping of secreted proteins to other therapeutic focus areas.” “Juvena has developed an unbiased computational drug discovery platform that allows it to uncover novel insights about the role of secreted proteins at an unprecedented scale, and ...
EST) on Wednesday, November 9 Event: Jefferies London Healthcare Conference, London Date: Tuesday, November 15 - Thursday, November 17 Participant: Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. Time: 8:35 a.m. GMT (3:35 a.m. EST) on Wednesday, November 16 About Jubilant Therapeutics Inc. Jubilant Therapeutics Inc. is a clinical ...
Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. ...
” “Despite decades of effort, many targets remain inaccessible to traditional small molecule drugs, and many others have uncertain relevance to disease,” said Vividion Therapeutics CEO Jeffrey Hatfield. “This collaboration brings together two orthogonal, highly innovative and synergistic approaches to drug discovery that will address both ...
ByBayer AG
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in ...